Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97(4):1566–71. https://doi.org/10.1073/pnas.97.4.1566.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takayanagi H. RANKL as the master regulator of osteoclast differentiation. J Bone Miner Metab. 2021;39(1):13–8. https://doi.org/10.1007/s00774-020-01191-1.

Article  CAS  PubMed  Google Scholar 

McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2008;12(1):35–46. https://doi.org/10.1007/s10456-008-9127-z.

Article  CAS  PubMed  Google Scholar 

Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The role of osteoprotegerin and its ligands in vascular function. Int J Mol Sci. 2019;20(3):705. https://doi.org/10.3390/ijms20030705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020;40(1):2. https://doi.org/10.1186/s41232-019-0111-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ming J, Cronin SJF, Penninger JM. Targeting the RANKL/RANK/OPG Axis for Cancer Therapy. Front Oncol. 2020;10:1283. https://doi.org/10.3389/fonc.2020.01283.

Article  PubMed  PubMed Central  Google Scholar 

Glasnovic A, O’Mara N, Kovacic N, Grcevic D, Gajovic S. RANK/RANKL/OPG Signaling in the Brain: A Systematic Review of the Literature. Front Neurol. 2020;11:590480. https://doi.org/10.3389/fneur.2020.590480.

Article  PubMed  PubMed Central  Google Scholar 

Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, et al. Central control of fever and female body temperature by RANKL/RANK. Nature. 2009;462(7272):505–9. https://doi.org/10.1038/nature08596.

Article  CAS  PubMed  Google Scholar 

Ikebuchi Y, Aoki S, Honma M, Hayashi M, Sugamori Y, Khan M, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. 2018;561(7722):195–200. https://doi.org/10.1038/s41586-018-0482-7.

Article  CAS  PubMed  Google Scholar 

Cariati I, Bonanni R, Onorato F, Mastrogregori A, Rossi D, Iundusi R, et al. Role of Physical Activity in Bone-Muscle Crosstalk: Biological Aspects and Clinical Implications. J Funct Morphol Kinesiol. 2021;6(2):55. https://doi.org/10.3390/jfmk6020055.

Article  PubMed  PubMed Central  Google Scholar 

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19. https://doi.org/10.1016/s0092-8674(00)80209-3.

Article  CAS  PubMed  Google Scholar 

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL. J Bone Miner Res. 2009;24(2):182–95. https://doi.org/10.1359/jbmr.081112.

Article  CAS  PubMed  Google Scholar 

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. https://doi.org/10.1056/NEJMoa0809493.

Article  CAS  PubMed  Google Scholar 

Pang KL, Low NY, Chin KY. A Review on the Role of Denosumab in Fracture Prevention. Drug Des Devel Ther. 2020;14:4029–51. https://doi.org/10.2147/DDDT.S270829.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dufresne SS, Dumont NA, Bouchard P, Lavergne É, Penninger JM, Frenette J. Osteoprotegerin protects against muscular dystrophy. Am J Pathol. 2015;185(4):920–6. https://doi.org/10.1016/j.ajpath.2015.01.006.

Article  CAS  PubMed  Google Scholar 

Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, et al. A Pooled Analysis of Fall Incidence From Placebo-controlled Trials of Denosumab. J Bone Miner Res. 2020;35(6):1014–21.

Article  CAS  PubMed  Google Scholar 

Bone GH, Bolognese AM, Yuen KC, Kendler LD, Wang LH, Liu LY, et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women. J Clin Endocrinol Metab. 2008;93(6):2149–57. https://doi.org/10.1210/jc.2007-2814.

Article  CAS  PubMed  Google Scholar 

Langdahl LB, Teglbjærg SC, Ho LP-R, Chapurlat MR, Czerwinski DE, Kendler AD, et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. J Clin Endocrinol Metabolism. 2015;100(4):1335–42. https://doi.org/10.1210/jc.2014-4079.

Article  CAS  Google Scholar 

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–82. https://doi.org/10.1200/JCO.2008.16.3832.

Article  CAS  PubMed  Google Scholar 

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55. https://doi.org/10.1056/NEJMoa0809003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phu S, Bani Hassan E, Vogrin S, Kirk B, Duque G. Effect of Denosumab on Falls, Muscle Strength, and Function in Community-Dwelling Older Adults. J Am Geriatr Soc. 2019;67(12):2660–1. https://doi.org/10.1111/jgs.16165.

Article  PubMed  Google Scholar 

Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019;129(8):3214–23. https://doi.org/10.1172/JCI125915.

Article  PubMed  PubMed Central  Google Scholar 

Rupp T, von Vopelius E, Strahl A, Oheim R, Barvencik F, Amling M, et al. Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporos Int. 2022;33(10):2177–84. https://doi.org/10.1007/s00198-022-06470-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lefkowitz SS, Lefkowitz DL, Kethley J. Treatment of facioscapulohumeral muscular dystrophy with Denosumab. Am J Case Rep. 2012;13:66–8. https://doi.org/10.12659/AJCR.882771.

Article  PubMed  PubMed Central  Google Scholar 

Ralston SH, Taylor JP. Rare Inherited forms of Paget’s Disease and Related Syndromes. Calcif Tissue Int. 2019;104(5):501–16. https://doi.org/10.1007/s00223-019-00520-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Theodorou SJ, Theodorou DJ. Global loss of bone, muscle, and fat mass in a patient with juvenile Paget disease (hereditary hyperphosphatasia). J Inherit Metab Dis. 2022;45(6):1203–4. https://doi.org/10.1002/jimd.12559.

Article  PubMed  Google Scholar 

Kerr NM, Cassinelli HR, DiMeglio LA, Tau C, Tüysüz B, Cundy T, et al. Ocular manifestations of juvenile Paget disease. Arch Ophthalmol. 2010;128(6):698–703. https://doi.org/10.1001/archophthalmol.2010.76.

Article  PubMed